Preclinical studies suggest that dexmedetomidine may promote cancer cell survival through the upregulation of HIF-1α, enhance metastasis via MMPs, and stimulate angiogenesis by increasing VEGF expression [159,160,161]. This evidence concerns the gene HIF1A and cancer.